| Title |
Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain
|
|---|---|
| Published in |
Journal of Pain Research, August 2014
|
| DOI | 10.2147/jpr.s36446 |
| Pubmed ID | |
| Authors |
Tracy L Skaer |
| Abstract |
Opioids continue to be first-line pharmacotherapy for patients suffering from cancer pain. Unfortunately, subtherapeutic dosage prescribing of pain medications remains common, and many cancer patients continue to suffer and experience diminished quality of life. A large variety of therapeutic options are available for cancer pain patients. Analgesic pharmacotherapy is based on the patient's self-report of pain intensity and should be tailored to meet the requirements of each individual. Most, if not all, cancer pain patients will ultimately require modifications in their opioid pharmacotherapy. When changes in a patient's medication regimen are needed, adequate pain control is best maintained through appropriate dosage conversion, scheduling immediate release medication for withdrawal prevention, and providing as needed dosing for breakthrough pain. Transdermal opioids are noninvasive, cause less constipation and sedation when compared to oral opioids, and may improve patient compliance. A relative potency of 100:1 is recommended when converting the patient from oral morphine to transdermal fentanyl. Based on the limited data available, there is significant interpatient variability with transdermal buprenorphine and equipotency recommendations from oral morphine of 75:1-110:1 have been suggested. Cancer patients may require larger transdermal buprenorphine doses to control their pain and may respond better to a more aggressive 75-100:1 potency ratio. This review outlines the prescribing of transdermal fentanyl and transdermal buprenorphine including how to safely and effectively convert to and use them for those with cancer pain. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 21% |
| Other | 9 | 13% |
| Student > Bachelor | 6 | 8% |
| Student > Postgraduate | 6 | 8% |
| Student > Master | 6 | 8% |
| Other | 15 | 21% |
| Unknown | 14 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 45% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Agricultural and Biological Sciences | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Arts and Humanities | 2 | 3% |
| Other | 9 | 13% |
| Unknown | 15 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 September 2014.
All research outputs
#17,286,645
of 25,374,917 outputs
Outputs from Journal of Pain Research
#1,316
of 1,979 outputs
Outputs of similar age
#143,236
of 240,212 outputs
Outputs of similar age from Journal of Pain Research
#10
of 15 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,979 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.2. This one is in the 23rd percentile – i.e., 23% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 240,212 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 20th percentile – i.e., 20% of its contemporaries scored the same or lower than it.